GALMED PHARMACEUTICALS LTD. Research and Development Expense
GALMED PHARMACEUTICALS LTD. (GLMD) reported Research and Development Expense of $1.78 million for the 3-month period ending 2026-06-30, per its 6-K filed 2026-09-02.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-09-02
- GALMED PHARMACEUTICALS LTD. research and development expense for the quarter ending 2026-06-30 was $1.78M, a 68.43% increase year-over-year.
- GALMED PHARMACEUTICALS LTD. research and development expense for the quarter ending 2025-12-31 was $2.10M, a 95.52% increase year-over-year.
- GALMED PHARMACEUTICALS LTD. research and development expense for the quarter ending 2025-09-30 was $1.09M, a 47.15% increase year-over-year.
- GALMED PHARMACEUTICALS LTD. research and development expense for the quarter ending 2025-06-30 was $1.06M, a 98.13% increase year-over-year.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.78M 6-K · filed 2026-09-02 | $3.14M 6-K · filed 2026-09-02 | ||
| 2025-12-31 | $2.10M derived: 20-F 12 month − 6-K 9 month · filed 2026-03-31 | $3.18M derived: sum of 2 quarters · filed 2026-03-31 | $4.24M derived: sum of 3 quarters · filed 2026-09-02 | $4.87M 20-F · filed 2026-03-31 |
| 2025-09-30 | $1.09M 6-K · filed 2025-11-26 | $2.14M derived: sum of 2 quarters · filed 2026-09-02 | $2.78M 6-K · filed 2025-11-26 | |
| 2025-06-30 | $1.06M 6-K · filed 2026-09-02 | $1.69M 6-K · filed 2026-09-02 | ||
| 2024-12-31 | $1.07M derived: 20-F 12 month − 6-K 9 month · filed 2026-03-31 | $1.81M derived: sum of 2 quarters · filed 2026-03-31 | $2.34M derived: sum of 3 quarters · filed 2026-03-31 | $2.98M 20-F · filed 2026-03-31 |
| 2024-09-30 | $738.00K 6-K · filed 2025-11-26 | $1.27M derived: sum of 2 quarters · filed 2025-11-26 | $1.91M 6-K · filed 2025-11-26 | |
| 2024-06-30 | $534.00K 6-K · filed 2025-08-28 | $1.17M 6-K · filed 2025-08-28 | ||
| 2023-12-31 | $3.57M 20-F · filed 2026-03-31 | |||
| 2023-06-30 | $809.00K 6-K · filed 2024-08-28 | $1.89M 6-K · filed 2024-08-28 | ||
| 2022-12-31 | $12.99M 20-F · filed 2025-04-02 | |||
| 2022-06-30 | $2.58M 6-K · filed 2023-08-09 | $7.38M 6-K · filed 2023-08-09 | ||
| 2021-12-31 | $27.22M 20-F · filed 2024-04-04 | |||
| 2021-06-30 | $7.04M 6-K · filed 2022-08-04 | $14.42M 6-K · filed 2022-08-04 | ||
| 2020-12-31 | $26.08M 20-F · filed 2023-03-29 | |||
| 2020-06-30 | $4.97M 6-K · filed 2021-08-05 | $10.52M 6-K · filed 2021-08-05 | ||
| 2019-12-31 | $18.18M 20-F · filed 2022-05-02 | |||
| 2019-06-30 | $3.49M 6-K · filed 2020-08-06 | $6.76M 6-K · filed 2020-08-06 | ||
| 2018-12-31 | $8.31M 20-F · filed 2021-03-18 | |||
| 2018-06-30 | $1.94M 6-K · filed 2019-08-05 | $3.88M 6-K · filed 2019-08-05 | ||
| 2017-12-31 | $9.65M 20-F · filed 2020-03-12 | |||
| 2017-06-30 | $2.35M 6-K · filed 2018-08-02 | $5.09M 6-K · filed 2018-08-02 | ||
| 2016-12-31 | $14.27M 20-F · filed 2019-03-13 | |||
| 2016-06-30 | $3.36M 6-K · filed 2017-07-31 | $6.74M 6-K · filed 2017-07-31 | ||
| 2015-12-31 | $7.63M 20-F · filed 2018-03-13 | |||
| 2015-06-30 | $1.56M 6-K · filed 2017-06-23 | $2.99M 6-K · filed 2017-06-23 | ||
| 2014-12-31 | $6.66M 20-F · filed 2017-03-23 | |||
| 2013-12-31 | $7.21M 20-F · filed 2016-03-22 | |||
| 2012-12-31 | $2.44M 20-F · filed 2015-03-31 |